TEM

In Q1 2026, Tempus AI reported revenue of $348.1 million, a 36.1% year-over-year increase, but posted a wider-than-expected GAAP net loss. A short-seller report in May 2025 alleged aggressive accounting practices, leading to a stock price drop and subsequent lawsuits. Tempus AI announced oncology collaborations with Merck & Co. and Gilead Sciences, and was named to TIME's list of the 10 Most Influential Health and Life Science Companies of 2026. Tempus announced a proposed offering of convertible senior notes to optimize its capital structure and reduce interest expense. Tempus AI's stock has experienced significant volatility over the past 12 months.